NEW YORK--(www.lgsfoundation.org to download and complete their application by the deadline of March 8, 2013.)--The Lennox-Gastaut Syndrome Foundation (LGS Foundation) and Lundbeck announced today the availability of a new Lundbeck Scholarship to provide financial assistance for families interested in attending the upcoming national 2013 LGS Foundation Family & Professional Conference in Cerritos, Calif., May 3-5. The application asks families to write a short essay explaining why they are interested in attending and how LGS has affected their family. Applicants can visit the LGS Foundation website,
“Because LGS is not a common seizure disorder, many families struggle to find local support, and some may never have had the opportunity to connect in person with another family coping with the condition”
Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy.1,2 The condition is typically diagnosed in childhood and often persists into adulthood.2,3,4 LGS can take an enormous toll on the physical and developmental health of the patient, as well as the well-being of the patient’s family, due to the severity of seizures, frequent injuries, developmental delays and behavioral problems of the patient.1,5
The Family & Professional Conference brings families and professionals together to discuss new developments in treatments and services available, as well as personal experiences with the condition. The scholarship, which is funded through a donation by Lundbeck, a pharmaceutical company committed to helping people with epilepsy, will cover travel, hotel accommodations and conference registration fees for selected families.
“Because LGS is not a common seizure disorder, many families struggle to find local support, and some may never have had the opportunity to connect in person with another family coping with the condition,” said Christina SanInocencio, president, Lennox-Gastaut Syndrome Foundation. “The Family & Professional Conference gives families from across the country a chance to have open discussion with others who understand the day-to-day challenges of LGS, and gives them interaction with LGS experts whom they might not have access to at a local level. The Lundbeck Scholarship makes it possible for more families to have this experience.”
All scholarship recipients will be selected by an LGS Foundation-appointed, independent board of reviewers. If selected, LGS Foundation will contact recipients to arrange travel to the conference before April 5, 2013. The LGS Foundation provides on-site childcare for LGS patients, allowing caregivers to attend discussions.
“We understand that families affected by LGS benefit from increased education and resources that can help them manage this challenging, and sometimes isolating, condition,” said Mike Hanley, Director of Marketing, Lundbeck US. “We have seen firsthand how important the LGS Foundation can be for these families, and are proud to offer the Lundbeck Scholarship to this year’s conference as part of our ongoing commitment to address the needs of people with challenging seizure disorders.”
About Lennox-Gastaut Syndrome Foundation
The LGS Foundation is a non-profit organization dedicated to providing information about Lennox-Gastaut Syndrome while raising funds for research, services and support for individuals living with LGS and their families. The LGS Foundation is based in New York City and provides services and information to thousands of members across the world.
About Lundbeck in the U.S.
A wholly-owned subsidiary of H. Lundbeck A/S, Lundbeck in the U.S. is headquartered in Deerfield, Illinois, and is committed to accelerating its work in central nervous system (CNS) disorders, including challenging seizure disorders. Additionally, Lundbeck employees actively support and participate in hundreds of epilepsy awareness events each year as part of their ongoing commitment to make a difference for those impacted by epilepsy. For more information, please visit YourPartnerInEpilepsy.com.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with psychiatric and neurological disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.
1. Glauser, Tracey. Lennox-Gastaut Syndrome. Medscape. 2011. http://emedicine.medscape.com/article/1176735-overview. Last accessed 1/9/13.
2. Van Rijckevorsel, Kenou et al. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatric Disease and Treatment. 2008: 4(6) 1001-1019.
3. Arzimanoglou, Alexis et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. The Lancet. 2009: 8(1) 82-93.
4. Cherian, K. Lennox-Gastaut Syndrome. Medscape. 2012. http://emedicine.medscape.com/article/1176735-overview. Last accessed 1/9/13.
5. Crumrine PK. Management of Seizures in Lennox-Gastaut Syndrome. Pediatric Drugs. 2011:13 (2): 107-118.